Living with breast cancer can be overwhelming, especially when it comes to treatment options. If you’ve been diagnosed with HR+, or hormone receptor-positive, breast cancer, your doctor may have recommended a combination of treatments tailored to your unique situation.
HR+ breast cancer is characterized by the presence of estrogen receptors on cancer cells. Estrogen can fuel the growth of these cells, so hormonal therapies aim to block its effects. Treatment for HR+ breast cancer typically involves a mix of medications that target different aspects of the disease, including hormone-blocking drugs, targeted therapies, and immunotherapies.
Treatment Options for HR+ Breast Cancer
- Endocrine Therapy: This is likely part of your treatment plan. Endocrine therapy can involve medications like tamoxifen or aromatase inhibitors, which block estrogen’s effects on cancer cells.
- Kinase Inhibitors: These targeted therapies aim to slow the growth and spread of cancer cells by blocking specific enzymes involved in their proliferation. Examples include lapatinib (Tykerb) and neratinib (Neroden).
- Biologics: Immunotherapies like trastuzumab (Herceptin), pertuzumab (Perjeta), and adjuvant therapy with trastuzumab and pertuzumab (Kadcyla) work by boosting your body’s immune system to fight cancer cells.
- Antibody-Drug Conjugates: These innovative treatments combine antibodies with chemotherapy drugs, delivering the latter directly to cancer cells. Examples include fam-trastuzumab deruxtecan (enhertu) and sacituzumab govitecan (Imfinzi).
When considering your treatment options, it’s essential to discuss relative effectiveness, quality-of-life implications, and cost with your healthcare provider. Some treatments may have more severe side effects than others, so weighing the benefits against the risks is crucial.
You can find more information on these treatments by visiting reputable sources like the American Cancer Society, National Cancer Institute, or the National Comprehensive Cancer Network.
Leave a Reply